Original ContributionQuantitative Computed Tomography Perfusion of Prostate Cancer: Correlation with Whole-Mount Pathology
References (31)
- et al.
Comparison of microscopic vasculatiry in benign and malignant prostate tissue
Human Pathol
(1993) - et al.
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies
Urology
(1996) Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review
Eur J Radiol
(1999)- et al.
Helical CT of prostate cancer: early clinical experience
AJR Am J Roentgenol
(2000) Measurement of tissue perfusion by dynamic computed tomography
Br J Radiol
(1991)- et al.
The staging and grading of prostatic caner
- et al.
The role of computed tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer
Semin Urol Oncol
(1998) - et al.
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
Am J Pathol
(1993) - et al.
Tumor-associated angiogenesis in prostate cancer
Anticancer Res
(1993) - et al.
Predictors of pathologic stage in prostate carcinoma. The role of neovascularity
Cancer
(1994)
Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
Prostate
Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
Br J Cancer
Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma
Cancer
Prostate: techniques, results and potential applications of color Doppler US scanning
Radiology
Color Doppler imaging and transrectal sonography of the prostatic fossa after radical prostatectomy: early experience
AJR Am J Roentgenol
Cited by (35)
Perfusion change in benign prostatic hyperplasia before and after castration in a canine model: Contrast enhanced ultrasonography and CT perfusion study
2020, TheriogenologyCitation Excerpt :Blood volume is the amount of blood contained within the vasculature of 1000 mL of tissue. Several studies have used CTP to evaluate cases with prostatic cancer [18–20]. However, to the best of the authors’ knowledge, perfusion changes in cases with BPH have not been investigated using CTP.
Segmentation of prostate contours for automated diagnosis using ultrasound images: A survey
2017, Journal of Computational ScienceIs primary tumor detectable in prostatic carcinoma at routine contrast-enhanced CT?
2015, Clinical ImagingCitation Excerpt :In our study, a subgroup analysis revealed a significant improvement in detection of GS 9–10 compared to GS 7–8 and score 6 tumors and a trend towards improved detection rates when comparing GS 7–8 to GS 6 tumors. This finding would be supported by other studies of dynamic CECT in prostatic carcinoma, which have shown a correlation between enhancement/perfusion at CECT and Gleason grade and microvessel density [23,24] and is also supported by the recent results by Glazer et al. which showed that focal enhancement is specific for GS ≥ 4=3=7 cancer [5]. The results of our study confirm our hypothesis that GS ≥ 7 primary tumors are reliably and reproducibly detectable at routine CECT.
PET in prostate and bladder tumors
2012, Seminars in Nuclear MedicineCitation Excerpt :The results of this meta-analysis suggest that FDG-PET or PET/CT provides good diagnostic accuracy of lymph nodes; however, the application of FDG-PET or PET/CT in diagnosis and localized staging of bladder cancer is in some instances restricted by radiotracer urinary excretion (Fig. 7). In the same meta-analysis, there were 4 studies which used intravenous injection of frusemide,97,9-100,101,104 with 2 using delayed pelvic images after oral hydration and diuretic administration.97,104 In a study of 11 patients with invasive bladder cancer by Anjos et al,97 the reported sensitivity and the specificity for detection of bladder wall lesions were both 100%.
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cancer Information Group, ISSN #1540-0352, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.